These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease. Loomba R; Wong VW Aliment Pharmacol Ther; 2024 Jan; 59(2):150-156. PubMed ID: 38153279 [TBL] [Abstract][Full Text] [Related]
6. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease. Younossi ZM; Paik JM; Stepanova M; Ong J; Alqahtani S; Henry L J Hepatol; 2024 May; 80(5):694-701. PubMed ID: 38286339 [TBL] [Abstract][Full Text] [Related]
8. Liver and atherosclerotic risks of patients with cryptogenic steatotic liver disease. Wang SW; Hsieh TH; Cheng YM; Wang CC; Kao JH Hepatol Int; 2024 Jun; 18(3):943-951. PubMed ID: 38227142 [TBL] [Abstract][Full Text] [Related]
9. Association of Metabolic Dysfunction-Associated Steatotic Liver Disease/Non-alcoholic Fatty Liver Disease With Type 2 Diabetes Mellitus: A Case-Control Study in a Tertiary Care Hospital in Pakistan. Zahoor F; Saeed NU; Javed S; Sadiq HZ; Mand Khan F; Haider M; Shafqat MN; Maqbool A; Chaudhry A Cureus; 2023 Oct; 15(10):e47240. PubMed ID: 38021965 [TBL] [Abstract][Full Text] [Related]
11. Therapeutic management of metabolic dysfunction associated steatotic liver disease. Zeng J; Fan JG; Francque SM United European Gastroenterol J; 2024 Mar; 12(2):177-186. PubMed ID: 38193865 [TBL] [Abstract][Full Text] [Related]
12. Exploring the landscape of steatotic liver disease in the general US population. Ciardullo S; Carbone M; Invernizzi P; Perseghin G Liver Int; 2023 Nov; 43(11):2425-2433. PubMed ID: 37592856 [TBL] [Abstract][Full Text] [Related]
13. Evidence that non-alcoholic fatty liver disease and polycystic ovary syndrome are associated by necessity rather than chance: a novel hepato-ovarian axis? Targher G; Rossini M; Lonardo A Endocrine; 2016 Feb; 51(2):211-21. PubMed ID: 26024975 [TBL] [Abstract][Full Text] [Related]
14. The Multicomponent Medicinal Product Hepar Compositum Reduces Hepatic Inflammation and Fibrosis in a Streptozotocin- and High-Fat Diet-Induced Model of Metabolic Dysfunction-Associated Steatotic Liver Disease/Metabolic Dysfunction-Associated Steatohepatitis. Burmeister Y; Weyer K; Dörre A; Seilheimer B Biomedicines; 2023 Dec; 11(12):. PubMed ID: 38137437 [TBL] [Abstract][Full Text] [Related]
15. Brazilian evidence-based guideline for screening, diagnosis, treatment, and follow-up of metabolic dysfunction-associated steatotic liver disease (MASLD) in adult individuals with overweight or obesity: A joint position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM), Brazilian Society of Hepatology (SBH), and Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso). Moreira RO; Valerio CM; Villela-Nogueira CA; Cercato C; Gerchman F; Lottenberg AMP; Godoy-Matos AF; Oliveira RA; Brandão Mello CE; Álvares-da-Silva MR; Leite NC; Cotrim HP; Parisi ER; Silva GF; Miranda PAC; Halpern B; Pinto Oliveira C Arch Endocrinol Metab; 2023 Nov; 67(6):e230123. PubMed ID: 38048417 [TBL] [Abstract][Full Text] [Related]
16. [Diagnosis and evaluation of metabolic dysfunction associated steatotic liver disease (MASLD)]. Canivet CM; Faure S Rev Med Interne; 2024 Jan; 45(1):41-47. PubMed ID: 38158295 [TBL] [Abstract][Full Text] [Related]
18. From NAFLD to MASLD: When metabolic comorbidity matters. Hong S; Sun L; Hao Y; Li P; Zhou Y; Liang X; Hu J; Wei H Ann Hepatol; 2024; 29(2):101281. PubMed ID: 38135250 [TBL] [Abstract][Full Text] [Related]
19. Non-alcoholic fatty liver disease is associated with insulin resistance and lipid accumulation product in women with polycystic ovary syndrome. Macut D; Tziomalos K; Božić-Antić I; Bjekić-Macut J; Katsikis I; Papadakis E; Andrić Z; Panidis D Hum Reprod; 2016 Jun; 31(6):1347-53. PubMed ID: 27076501 [TBL] [Abstract][Full Text] [Related]
20. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Targher G; Byrne CD; Tilg H Gut; 2024 Mar; 73(4):691-702. PubMed ID: 38228377 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]